Qube Research & Technologies (QRT)
CYTK icon

Qube Research & Technologies (QRT)’s Cytokinetics CYTK Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$48.8M Sell
572,535
-206,911
-27% -$14.9M 0.05% 506
2026
Q1 		$51.4M Buy
779,446
+242,169
+45% +$15.4M 0.06% 420
2025
Q4 		$34.1M Buy
537,277
+528,239
+5,845% +$32.9M 0.03% 655
2025
Q3 		$497K Sell
9,038
-112,784
-93% -$4.65M ﹤0.01% 2722
2025
Q2 		$4.02M Buy
121,822
+4,602
+4% +$160K ﹤0.01% 1836
2025
Q1 		$4.71M Buy
117,220
+53,690
+85% +$2.47M 0.01% 1573
2024
Q4 		$2.99M Buy
+63,530
New +$3.3M ﹤0.01% 1720
2024
Q3 		– Sell
-1,466
Closed -$79.4K – 3465
2024
Q2 		$79.4K Sell
1,466
-28,562
-95% -$1.72M ﹤0.01% 2645
2024
Q1 		$2.11M Sell
30,028
-320,507
-91% -$24.8M ﹤0.01% 1724
2023
Q4 		$29.3M Buy
350,535
+340,827
+3,511% +$12.3M 0.06% 405
2023
Q3 		$286K Sell
9,708
-85,848
-90% -$2.86M ﹤0.01% 2267
2023
Q2 		$3.12M Sell
95,556
-6,942
-7% -$257K 0.01% 868
2023
Q1 		$3.61M Buy
+102,498
New +$4.18M 0.02% 766
2021
Q4 		– Sell
-12,374
Closed -$442K – 2601
2021
Q3 		$442K Buy
+12,374
New +$364K 0.01% 1274
2020
Q4 		– Sell
-13,748
Closed -$298K – 1878
2020
Q3 		$298K Sell
13,748
-10,091
-42% -$236K ﹤0.01% 1249
2020
Q2 		$562K Buy
+23,839
New +$447K 0.01% 1068

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Qube Research & Technologies (QRT)'s CYTK Position: Q2 2026 in Review

Qube Research & Technologies (QRT) reduced its Cytokinetics (CYTK) stake by 27% in Q2 2026, selling an estimated $14.9M and leaving 572,535 shares worth $48.8M. The position accounts for 0.05% of the portfolio, ranked #506.

Qube Research & Technologies (QRT) first reported a position in CYTK in Q2 2020 and has held it in 16 quarters since. The position peaked at $51.4M in Q1 2026. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Qube Research & Technologies (QRT) held 572,535 shares of Cytokinetics worth $48.8M as of Q2 2026.
  • Qube Research & Technologies (QRT) sold 206,911 Cytokinetics shares in Q2 2026, an estimated $14.9M.
  • Cytokinetics made up 0.05% of Qube Research & Technologies (QRT)'s portfolio in Q2 2026, its #506 holding.
  • Qube Research & Technologies (QRT) first reported a position in Cytokinetics in Q2 2020 and has held it in 16 quarters since.
  • Qube Research & Technologies (QRT)'s Cytokinetics position peaked at $51.4M in Q1 2026.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q2 2026, filed 14 Aug 2026.